孟鲁司特钠对稳定期慢性阻塞性肺疾病患者肺功能和血清白细胞介素-8、白细胞介素-10等指标的影响

Effects of Montelukast Sodium on the Lung Function and Serum IL-8 and IL-10 in Patients with Stable Chronic Obstructive Pulmonary Disease

目的:研究孟鲁司特钠(montelukast sodium,MS)对于稳定期(stable period,SP)慢性阻塞性肺疾病(COPD)患者肺功能和血清白细胞介素-8(IL-8)、白细胞介素-10(IL-10)等指标的影响。方法:将2013年1—8月共60例在我院的呼吸内科接受治疗的SP COPD患者以随机抽样法分成常规组(30例)及MS组(30例)。常规组实施常规疗法,MS组则另加服MS;另选同期在我院接受体检的30例健康者作为对照组。测定患者血清IL-8、IL-10与血液流变学相关指标以及肺功能指标,进行对比分析。结果:MS组临床疗效显著优于对照组,差异有统计学意义(P<0.05)。COPD患者(含MS组及常规组)在治疗前的血液流变学指标水平显著高于对照组,差异有统计学意义(P<0.05)。相比于治疗前,MS组患者治疗后的IL-10、第一秒用力呼气量(FEV1)及用力肺活量(FVC)的比值(FEV1/FVC)、FEV1占预计值的百分比(FEV1/预计值,FEV1%)等水平明显上升(P<0.05);而IL-8及血液流变学等指标水平均明显下降(P<0.05)。相比于对照组治疗后,MS组患者治疗后的全血高切黏度(HSR)、全血低切黏度(LSR)、血浆黏度(ηp)、血沉(ESR)、红细胞压积(HCT)、血浆纤维蛋白原(FIB)、IL-8均下降,但IL-10、FEV1%、FEV1/FVC等水平明显上升,差异均有统计学意义(P<0.05)。结论:MS治疗SP COPD患者具有较好的疗效,值得临床推荐。

OBJECTIVE：To study the effects of Montelukast sodium（MS） on the lung function and serum IL-8 and IL-10 in patients with stable chronic obstructive pulmonary disease （COPD）. METHODS：From January 2013 to August 2013,60 patients with stable COPD in the Department of Respiratory Medicine of our hospital were randomized to either conventional group （ conventional therapy） or MS group （ conventional therapy plus MS ） of 30 cases each. Moreover, another 30 healthy volunteers were assigned to control group. Serum IL-8, IL-10, hemorheology, and pulmonary function of the patients were measured and a contrast analysis was performed. RESULTS：The clinical efficacy in MS group was significantly better than in the control group, and the differences were statistically significant （ P 〈 0. 05 ）. The hemorheological indexes before treatment were significantly higher in COPD patients （including MS group and the conventional group） than in control group and the differences were statistically significant （ P 〈 0. 05 ）. Compared to before treatment,IL-10, FEV1/FVC and FEVI% （FEV1/predicated value）in MS group were increased significantly after treatment（ all P 〈 0. 05 ） ; however, IL-8 and hemorheological indexes were decreased significantly（ all P 〈 0.05 ）. Compared to the control group after treatment, MS group showed reduction in HSR, LSR, P, ESR, HCT, FIB and IL-8 but increase in IL-10, FEVI%, FEV1/FVC after treatment, with differences statistically significant （ all P 〈 0. 05 ）. CONCLUSION：MS is effective for patients with stable COPD,which thus is worthy of clinical recommendation.